Atelvia Approval History
Atelvia (risedronate sodium) is a bisphosphonate in a delayed-release formulation for treatment of postmenopausal osteoporosis.
Development History and FDA Approval Process for Atelvia
|Oct 11, 2010||Warner Chilcott Announces FDA Approval of Atelvia - Next Generation Actonel|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.